JPRN-UMIN000015376已完成2 期
Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic cancer - modified FOLFIRINOX Study
Gifu University Hospital0 个研究点目标入组 28 人开始时间: 2014年10月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pulmonary fibrosis or interstitial pneumonia Watery stool Infection Uncontrolled diabetes mellitus Any serious complication Use of Atazanavir, Flucytosine, Phenytoin, and Warfarin potassium Pregnancy
研究者
相似试验
进行中（未招募）
不适用
A phase II study of modified FOLFIRINOX(5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for advanced biliary tract cancer after gemcitabine based chemotherapy failureKCT0004433Gyeongsang National University Hospital34
已完成
2 期
Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic canceruntreated metastatic pancreatic cancerJPRN-UMIN000013301Cancer Institute Hospital65
已完成
2 期
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2)locally advanced pancreatic cancerJPRN-UMIN000023143Japan Clinical Oncology Group (JCOG)124
招募中
2 期
Phase II study of modified FOLFIRINOX as neoadjuvant chemotherapy for borderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancerborderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancerJPRN-UMIN000015707Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery23
已完成
不适用
Phase I study of third-line FOLFIRINOX (oxaliplatin, irinotecan, 5-FU, and leucovorin) unresectable Gem/S-1 refractory pancreatic adenocarcinomaunresectable Gem/S-1 refractory pancreatic adenocarcinomaJPRN-UMIN000021526Osaka Medical Center for Cancer and Cardiovascular Diseases Division of Hepatobiliary and Pancreatic Oncology60